picking trials from CT.gov

schema of CT.gov tables is here http://aact.ctti-clinicaltrials.org/schema

library(RPostgreSQL)
## Loading required package: DBI
drv <- dbDriver('PostgreSQL')
#NLM previously blocked this port, had to ask for a hole in firewall :-(
con <- dbConnect(drv, dbname="aact",host="aact-prod.cr4nrslb1lw7.us-east-1.rds.amazonaws.com", port=5432, user="aact", password="aact")
counts <- dbGetQuery(con, "select study_type, count(*) as cnt from studies group by 1")
#indeed has a lot of new data
sum(counts$cnt)
## [1] 242222
#print the results
knitr::kable(counts)
study_type cnt
N/A 687
Observational 44233
Interventional 194035
Observational [Patient Registry] 2851
Expanded Access 416 
# sql<-"select nct_id from studies where study_type = 'Interventional' and number_of_arms=1"

#2 arms studies
sql<-"select * from studies where first_received_date < '2016-02-16' and study_type = 'Interventional' and number_of_arms=2 and enrollment > 200 
and first_received_results_date > '2016-01-01'
and nct_id in (select nct_id from interventions where intervention_type = 'Drug')
and nct_id in (select nct_id from interventions where upper(name) like '%PLACEBO%') 
and nct_id in (select nct_id from interventions group by nct_id having count(*) =2)
"


subsetA<-dbGetQuery(con, sql)
 # knitr::kable(dbGetQuery(con, sql));

  #49257 studies
 nrow(subsetA)
## [1] 105
 names(subsetA)
##  [1] "nct_id"                           
##  [2] "nlm_download_date_description"    
##  [3] "first_received_date"              
##  [4] "last_changed_date"                
##  [5] "first_received_results_date"      
##  [6] "received_results_disposit_date"   
##  [7] "start_month_year"                 
##  [8] "start_date_type"                  
##  [9] "start_date"                       
## [10] "verification_month_year"          
## [11] "verification_date"                
## [12] "completion_month_year"            
## [13] "completion_date_type"             
## [14] "completion_date"                  
## [15] "primary_completion_month_year"    
## [16] "primary_completion_date_type"     
## [17] "primary_completion_date"          
## [18] "target_duration"                  
## [19] "study_type"                       
## [20] "acronym"                          
## [21] "baseline_population"              
## [22] "brief_title"                      
## [23] "official_title"                   
## [24] "overall_status"                   
## [25] "last_known_status"                
## [26] "phase"                            
## [27] "enrollment"                       
## [28] "enrollment_type"                  
## [29] "source"                           
## [30] "limitations_and_caveats"          
## [31] "number_of_arms"                   
## [32] "number_of_groups"                 
## [33] "why_stopped"                      
## [34] "has_expanded_access"              
## [35] "expanded_access_type_individual"  
## [36] "expanded_access_type_intermediate"
## [37] "expanded_access_type_treatment"   
## [38] "has_dmc"                          
## [39] "is_fda_regulated_drug"            
## [40] "is_fda_regulated_device"          
## [41] "is_unapproved_device"             
## [42] "is_ppsd"                          
## [43] "is_us_export"                     
## [44] "biospec_retention"                
## [45] "biospec_description"              
## [46] "plan_to_share_ipd"                
## [47] "plan_to_share_ipd_description"    
## [48] "created_at"                       
## [49] "updated_at"
 write_csv(subsetA,'RCT-A-03.csv')
 
 
 #see the inverventions
 library(tidyverse)
 sql2<-sprintf('select * from interventions where nct_id in (select nct_id from (%s) tta )',sql)
 sql2
## [1] "select * from interventions where nct_id in (select nct_id from (select * from studies where first_received_date < '2016-02-16' and study_type = 'Interventional' and number_of_arms=2 and enrollment > 200 \nand first_received_results_date > '2016-01-01'\nand nct_id in (select nct_id from interventions where intervention_type = 'Drug')\nand nct_id in (select nct_id from interventions where upper(name) like '%PLACEBO%') \nand nct_id in (select nct_id from interventions group by nct_id having count(*) =2)\n) tta )"
 interventionsA<-dbGetQuery(con, sql2)
 
 write_csv(subsetA,'RCT-B-01.csv')
 
url<-'https://clinicaltrials.gov/ct2/show'
interventionsA$link=sprintf('%s/%s',url,interventionsA$nct_id)




 knitr::kable(interventionsA)
id nct_id intervention_type name description link
649794 NCT02466425 Drug SHP465 12.5mg and 25mg capsules (one capsule daily) https://clinicaltrials.gov/ct2/show/NCT02466425
649795 NCT02466425 Drug Placebo Matching placebo capsule that appear identical in size, weight, shape, color https://clinicaltrials.gov/ct2/show/NCT02466425
669758 NCT02320396 Drug Desloratadine 5 mg Desloratadine 5 mg tablets https://clinicaltrials.gov/ct2/show/NCT02320396
669759 NCT02320396 Drug Placebo Placebo tablets https://clinicaltrials.gov/ct2/show/NCT02320396
673124 NCT02294461 Drug Enzalutamide Oral https://clinicaltrials.gov/ct2/show/NCT02294461
673125 NCT02294461 Drug Placebo Oral https://clinicaltrials.gov/ct2/show/NCT02294461
674011 NCT02288273 Drug Bydureon Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks. https://clinicaltrials.gov/ct2/show/NCT02288273
674012 NCT02288273 Drug Placebo Placebo https://clinicaltrials.gov/ct2/show/NCT02288273
674494 NCT02284516 Drug Lifitegrast Lifitegrast Ophthalmic Solution 5%, BID for 84 days https://clinicaltrials.gov/ct2/show/NCT02284516
674495 NCT02284516 Drug Placebo Placebo to match active treatment, BID for 84 days https://clinicaltrials.gov/ct2/show/NCT02284516
675784 NCT02274948 Drug Metformin Metformin in the form of 500mg tablets were administer to the Metformin group https://clinicaltrials.gov/ct2/show/NCT02274948
675785 NCT02274948 Drug Placebo A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used https://clinicaltrials.gov/ct2/show/NCT02274948
679531 NCT02248818 Drug AZD8108 Drug: AZD8108 Single or Multiple doses administered orally as a solution. https://clinicaltrials.gov/ct2/show/NCT02248818
679532 NCT02248818 Drug Placebo Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution https://clinicaltrials.gov/ct2/show/NCT02248818
679579 NCT02248480 Drug Duloxetine Administered orally https://clinicaltrials.gov/ct2/show/NCT02248480
679580 NCT02248480 Drug Placebo Administered orally https://clinicaltrials.gov/ct2/show/NCT02248480
683334 NCT02219932 Drug fampridine NA https://clinicaltrials.gov/ct2/show/NCT02219932
683335 NCT02219932 Drug Placebo Matched placebo https://clinicaltrials.gov/ct2/show/NCT02219932
685824 NCT02201940 Drug SOF/VEL 400/100 mg FDC tablet administered orally once daily https://clinicaltrials.gov/ct2/show/NCT02201940
685825 NCT02201940 Drug Placebo Tablet administered orally once daily https://clinicaltrials.gov/ct2/show/NCT02201940
691789 NCT02157298 Drug Dapagliflozin 5 mg Dapagliflozin, a blood glucose lowering drug. Oral dose https://clinicaltrials.gov/ct2/show/NCT02157298
691790 NCT02157298 Drug Placebo tablet Placebo tablet. Oral dose https://clinicaltrials.gov/ct2/show/NCT02157298
696663 NCT02120027 Drug Ibodutant 10 mg Oral tablet, to be given once daily. https://clinicaltrials.gov/ct2/show/NCT02120027
696664 NCT02120027 Drug Placebo Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily. https://clinicaltrials.gov/ct2/show/NCT02120027
698404 NCT02107196 Drug Ibodutant 10 mg Oral tablet, to be given once daily. https://clinicaltrials.gov/ct2/show/NCT02107196
698405 NCT02107196 Drug Placebo Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily. https://clinicaltrials.gov/ct2/show/NCT02107196
698615 NCT02105688 Drug Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A) Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks. https://clinicaltrials.gov/ct2/show/NCT02105688
698616 NCT02105688 Drug Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks. https://clinicaltrials.gov/ct2/show/NCT02105688
698643 NCT02105467 Drug Grazoprevir 100mg / Elbasvir 50 mg FDC NA https://clinicaltrials.gov/ct2/show/NCT02105467
698644 NCT02105467 Drug Placebo to Grazoprevir / Elbasvir 50 mg FDC NA https://clinicaltrials.gov/ct2/show/NCT02105467
699815 NCT02096705 Drug Dapagliflozin NA https://clinicaltrials.gov/ct2/show/NCT02096705
699816 NCT02096705 Drug Dapagliflozin Placebo NA https://clinicaltrials.gov/ct2/show/NCT02096705
700568 NCT02090764 Drug Ozenoxacin NA https://clinicaltrials.gov/ct2/show/NCT02090764
700569 NCT02090764 Drug Placebo NA https://clinicaltrials.gov/ct2/show/NCT02090764
707917 NCT02034162 Drug Mebendazole Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child. https://clinicaltrials.gov/ct2/show/NCT02034162
707918 NCT02034162 Drug Placebo Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child. https://clinicaltrials.gov/ct2/show/NCT02034162
710999 NCT02009163 Drug Lisdexamfetamine dimesylate SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods) https://clinicaltrials.gov/ct2/show/NCT02009163
711000 NCT02009163 Other Placebo Placebo capsule once per day (double-blind period) https://clinicaltrials.gov/ct2/show/NCT02009163
713667 NCT01987960 Drug Placebo Once daily, tablets, orally https://clinicaltrials.gov/ct2/show/NCT01987960
713668 NCT01987960 Drug Brexpiprazole 1 to 3 mg/day, once daily dose, tablets, orally https://clinicaltrials.gov/ct2/show/NCT01987960
714420 NCT01982292 Drug RLX030 (serelaxin) RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours. https://clinicaltrials.gov/ct2/show/NCT01982292
714421 NCT01982292 Drug Placebo Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours. https://clinicaltrials.gov/ct2/show/NCT01982292
720963 NCT01931475 Drug Duloxetine Administered orally https://clinicaltrials.gov/ct2/show/NCT01931475
720964 NCT01931475 Drug Placebo Administered orally https://clinicaltrials.gov/ct2/show/NCT01931475
721695 NCT01925768 Drug Apremilast 30 mg 30mg of Apremilast will be orally administered twice daily for 104 weeks https://clinicaltrials.gov/ct2/show/NCT01925768
721696 NCT01925768 Drug Placebo Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks https://clinicaltrials.gov/ct2/show/NCT01925768
724704 NCT01903265 Drug TNX-102 SL 2.8mg Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks. https://clinicaltrials.gov/ct2/show/NCT01903265
724705 NCT01903265 Drug Placebo Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks. https://clinicaltrials.gov/ct2/show/NCT01903265
724813 NCT01902303 Drug Matching Placebo Sublingual micro dosing of placebo for 7 days https://clinicaltrials.gov/ct2/show/NCT01902303
724814 NCT01902303 Drug BTL-TML-HSV Sublingual micro dosing of BTL-TML-HSV for 7 days https://clinicaltrials.gov/ct2/show/NCT01902303
727688 NCT01880424 Drug Placebo matching Placebo Capsules, Oral, once daily https://clinicaltrials.gov/ct2/show/NCT01880424
727689 NCT01880424 Drug Linaclotide Linaclotide 290 ug Capsules, Oral, once daily https://clinicaltrials.gov/ct2/show/NCT01880424
728153 NCT01876784 Drug Vandetanib (SAR390530) Pharmaceutical form: tablet
Route of administration : oral https://clinicaltrials.gov/ct2/show/NCT01876784
728154 NCT01876784 Drug Placebo Pharmaceutical form: tablet
Route of administration : oral https://clinicaltrials.gov/ct2/show/NCT01876784
731847 NCT01848210 Drug Coumarin/troxerutin Coumarin + troxerutin fixed-dose combination tablets https://clinicaltrials.gov/ct2/show/NCT01848210
731848 NCT01848210 Drug Placebo Coumarin + troxerutin placebo-matching tablets https://clinicaltrials.gov/ct2/show/NCT01848210
736002 NCT01815840 Drug Vismodegib Vismodegib 150 mg hard gelatin capsule orally once daily https://clinicaltrials.gov/ct2/show/NCT01815840
736003 NCT01815840 Drug Placebo Vismodegib placebo orally once daily https://clinicaltrials.gov/ct2/show/NCT01815840
737894 NCT01800968 Drug Liraglutide Active Drug https://clinicaltrials.gov/ct2/show/NCT01800968
737895 NCT01800968 Drug Placebo Placebo https://clinicaltrials.gov/ct2/show/NCT01800968
738665 NCT01794000 Drug Prasugrel Administered orally https://clinicaltrials.gov/ct2/show/NCT01794000
738666 NCT01794000 Drug Placebo Administered orally https://clinicaltrials.gov/ct2/show/NCT01794000
738982 NCT01792518 Drug Placebo NA https://clinicaltrials.gov/ct2/show/NCT01792518
738983 NCT01792518 Drug Linagliptin 5mg NA https://clinicaltrials.gov/ct2/show/NCT01792518
739287 NCT01789970 Drug Hydrocodone ER During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.
Hydrocodo ne ER was take n by participants ra ndomized to the hydrocodone ER treatment arm during the double-blind treatment period at t he dose level identified during the titration period.
Participa nts were instr ucted to take tablet s with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating . https://clinicaltrials.gov/ct2/show/NCT01789970
739288 NCT01789970 Drug Placebo Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.
Participa nts were instr ucted to take interv ention with a glass of water on an empty stomach at least 1 hour before or 2 hours after e ating. https://clinicaltrials.gov/ct2/show/NCT01789970
739516 NCT01788046 Drug Etelcalcetide Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg. https://clinicaltrials.gov/ct2/show/NCT01788046
739517 NCT01788046 Drug Placebo Administered intravenously (IV) three times per week. https://clinicaltrials.gov/ct2/show/NCT01788046
739783 NCT01785849 Drug Etelcalcetide Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg. https://clinicaltrials.gov/ct2/show/NCT01785849
739784 NCT01785849 Drug Placebo Administered intravenously (IV) three times per week. https://clinicaltrials.gov/ct2/show/NCT01785849
741150 NCT01774604 Drug Indomethacin 100 mg Indomethacin PR x 1 https://clinicaltrials.gov/ct2/show/NCT01774604
741151 NCT01774604 Drug Placebo NA https://clinicaltrials.gov/ct2/show/NCT01774604
741794 NCT01769196 Drug Simtuzumab 125 mg/mL single-dose vials administered subcutaneously once a week https://clinicaltrials.gov/ct2/show/NCT01769196
741795 NCT01769196 Drug Simtuzumab placebo Simtuzumab placebo single-dose vials administered subcutaneously once a week https://clinicaltrials.gov/ct2/show/NCT01769196
745042 NCT01743729 Drug Lifitegrast Lifitegrast Ophthalmic Solution 5.0% https://clinicaltrials.gov/ct2/show/NCT01743729
745043 NCT01743729 Drug Placebo Placebo for Lifitegrast Ophthalmic Solution 5.0% https://clinicaltrials.gov/ct2/show/NCT01743729
746074 NCT01735630 Drug ELND005 NA https://clinicaltrials.gov/ct2/show/NCT01735630
746075 NCT01735630 Drug Placebo NA https://clinicaltrials.gov/ct2/show/NCT01735630
751813 NCT01691248 Drug fidaxomicin Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).
Study dru g treatment wi ll stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administer ed or neutrophil engraftment extends beyond 40 days. https://clinicaltrials.gov/ct2/show/NCT01691248
751814 NCT01691248 Drug Placebo Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).
Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutr ophil engraftment extends beyond 40 days. https://clinicaltrials.gov/ct2/show/NCT01691248
752502 NCT01685684 Drug Oxycodone DETERx 40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h https://clinicaltrials.gov/ct2/show/NCT01685684
752503 NCT01685684 Drug Placebo Placebo, divided into 2 doses, q12h https://clinicaltrials.gov/ct2/show/NCT01685684
753740 NCT01675661 Drug N-Acetylcysteine Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions. https://clinicaltrials.gov/ct2/show/NCT01675661
753741 NCT01675661 Drug Placebo Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions. https://clinicaltrials.gov/ct2/show/NCT01675661
754594 NCT01668797 Drug Brexpiprazole Brexpiprazole tablets 1 to 4 mg /day https://clinicaltrials.gov/ct2/show/NCT01668797
754595 NCT01668797 Drug Placebo Placebo comparator for 52 weeks https://clinicaltrials.gov/ct2/show/NCT01668797
754710 NCT01667679 Drug 100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally NA https://clinicaltrials.gov/ct2/show/NCT01667679
754711 NCT01667679 Drug OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet NA https://clinicaltrials.gov/ct2/show/NCT01667679
758694 NCT01636206 Drug Lifitegrast Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year https://clinicaltrials.gov/ct2/show/NCT01636206
758695 NCT01636206 Drug Placebo Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year https://clinicaltrials.gov/ct2/show/NCT01636206
760887 NCT01618162 Drug insulin degludec/liraglutide Injected subcutaneously (under the skin) once daily. Dose individually adjusted. https://clinicaltrials.gov/ct2/show/NCT01618162
760888 NCT01618162 Drug placebo Injected subcutaneously (under the skin) once daily. https://clinicaltrials.gov/ct2/show/NCT01618162
762784 NCT01602510 Drug Lamotrigine in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization https://clinicaltrials.gov/ct2/show/NCT01602510
762785 NCT01602510 Drug Placebo Placebo https://clinicaltrials.gov/ct2/show/NCT01602510
765381 NCT01582854 Drug Actovegin Actovegin solution for infusion and Actovegin tablets https://clinicaltrials.gov/ct2/show/NCT01582854
765382 NCT01582854 Drug Placebo Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets https://clinicaltrials.gov/ct2/show/NCT01582854
765883 NCT01578850 Drug Etanercept etanercept 50mg once weekly + methotrexate with or without other DMARDs https://clinicaltrials.gov/ct2/show/NCT01578850
765884 NCT01578850 Drug placebo etanercept placebo once weekly + methotrexate with or without other DMARDs https://clinicaltrials.gov/ct2/show/NCT01578850
766883 NCT01571362 Drug ALO-02 20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily https://clinicaltrials.gov/ct2/show/NCT01571362
766884 NCT01571362 Drug Placebo oral placebo, divided into symmetric doses and administered twice daily https://clinicaltrials.gov/ct2/show/NCT01571362
772942 NCT01524783 Drug Everolimus After randomization, patients will receive everolimus once daily until disease progression, intolerable toxicity, or consent withdrawal https://clinicaltrials.gov/ct2/show/NCT01524783
772943 NCT01524783 Drug Everolimus Placebo After randomization, patients will receive everolimus placebo once daily until disease progression, intolerable toxicity, or consent withdrawal https://clinicaltrials.gov/ct2/show/NCT01524783
774407 NCT01513291 Drug MK-6096 MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily https://clinicaltrials.gov/ct2/show/NCT01513291
774408 NCT01513291 Drug Placebo Placebo, 2 tablets, orally, once daily https://clinicaltrials.gov/ct2/show/NCT01513291
774992 NCT01508936 Drug Reslizumab Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses). https://clinicaltrials.gov/ct2/show/NCT01508936
774993 NCT01508936 Drug Placebo Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses). https://clinicaltrials.gov/ct2/show/NCT01508936
775029 NCT01508702 Drug lesinurad Tablets, 400 mg QD https://clinicaltrials.gov/ct2/show/NCT01508702
775030 NCT01508702 Drug Placebo Tablets, Placebo QD https://clinicaltrials.gov/ct2/show/NCT01508702
780749 NCT01465763 Drug tofacitinib 10 mg oral BID https://clinicaltrials.gov/ct2/show/NCT01465763
780750 NCT01465763 Drug Placebo Plabebo oral BID https://clinicaltrials.gov/ct2/show/NCT01465763
780959 NCT01464307 Drug IncobotulinumtoxinA (400 Units) Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection. https://clinicaltrials.gov/ct2/show/NCT01464307
780960 NCT01464307 Drug Placebo Comparator Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection https://clinicaltrials.gov/ct2/show/NCT01464307
781645 NCT01458951 Drug tofacitinib 10 mg oral BID https://clinicaltrials.gov/ct2/show/NCT01458951
781646 NCT01458951 Drug Placebo Placebo oral BID https://clinicaltrials.gov/ct2/show/NCT01458951
783618 NCT01443845 Drug Roflumilast Roflumilast 500 µg, oral administration, once per day https://clinicaltrials.gov/ct2/show/NCT01443845
783619 NCT01443845 Drug Placebo Dose-matched placebo, oral administration, once per day. https://clinicaltrials.gov/ct2/show/NCT01443845
783866 NCT01442038 Drug Ranolazine Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.
Subjects receiving a mo derate CYP3A4 inhibi tor will receive ranolazine 500 mg or placebo administered orally twice a day for the dura tion of the concomitant therapy. https://clinicaltrials.gov/ct2/show/NCT01442038
783867 NCT01442038 Drug Placebo Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.
Subjects receiving a mo derate CYP3A4 inhibi tor will receive ranolazine 500 mg or placebo administered orally twice a day for the dura tion of the concomitant therapy. https://clinicaltrials.gov/ct2/show/NCT01442038
788706 NCT01404208 Drug D-Cycloserine 25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session. https://clinicaltrials.gov/ct2/show/NCT01404208
788707 NCT01404208 Drug Placebo Sugar pill https://clinicaltrials.gov/ct2/show/NCT01404208
790150 NCT01392300 Drug IncobotulinumtoxinA (400 Units) Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection https://clinicaltrials.gov/ct2/show/NCT01392300
790151 NCT01392300 Drug Placebo Comparator Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection https://clinicaltrials.gov/ct2/show/NCT01392300
794435 NCT01358357 Drug Lurasidone Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter https://clinicaltrials.gov/ct2/show/NCT01358357
794436 NCT01358357 Drug Placebo 20-80 mg flexible dose https://clinicaltrials.gov/ct2/show/NCT01358357
794776 NCT01355484 Drug GTx-024 subjects will be randomized to receive GTx-024 for the full duration of the trial. https://clinicaltrials.gov/ct2/show/NCT01355484
794777 NCT01355484 Drug placebo subject will receive placebo for the duration of the trial https://clinicaltrials.gov/ct2/show/NCT01355484
796051 NCT01345253 Drug Belimumab 10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study. https://clinicaltrials.gov/ct2/show/NCT01345253
796052 NCT01345253 Drug Placebo Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study. https://clinicaltrials.gov/ct2/show/NCT01345253
798025 NCT01330030 Drug Selegiline 6mg/24 hrs for 8 weeks https://clinicaltrials.gov/ct2/show/NCT01330030
798026 NCT01330030 Other matching placebo placebo/24hrs for 8 weeks https://clinicaltrials.gov/ct2/show/NCT01330030
803444 NCT01287039 Drug Reslizumab Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses. https://clinicaltrials.gov/ct2/show/NCT01287039
803445 NCT01287039 Drug Placebo Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient’s body weight. https://clinicaltrials.gov/ct2/show/NCT01287039
803657 NCT01285323 Drug Reslizumab Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses. https://clinicaltrials.gov/ct2/show/NCT01285323
803658 NCT01285323 Drug Placebo Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses. https://clinicaltrials.gov/ct2/show/NCT01285323
804140 NCT01281202 Drug Vigabatrin Tablets https://clinicaltrials.gov/ct2/show/NCT01281202
804141 NCT01281202 Drug Matching Placebo Tablets https://clinicaltrials.gov/ct2/show/NCT01281202
804462 NCT01278745 Biological Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper) NA https://clinicaltrials.gov/ct2/show/NCT01278745
804463 NCT01278745 Drug Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper) NA https://clinicaltrials.gov/ct2/show/NCT01278745
808549 NCT01246973 Drug Curcumin 4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week https://clinicaltrials.gov/ct2/show/NCT01246973
808550 NCT01246973 Drug Placebo 4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week https://clinicaltrials.gov/ct2/show/NCT01246973
810987 NCT01228175 Drug Placebo 25mg look alike riboflavin tablets to match active study medication. https://clinicaltrials.gov/ct2/show/NCT01228175
810988 NCT01228175 Drug Varenicline Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily https://clinicaltrials.gov/ct2/show/NCT01228175
815400 NCT01194154 Drug Methoxy polyethylene glycol-epoetin beta Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL). https://clinicaltrials.gov/ct2/show/NCT01194154
815401 NCT01194154 Drug Placebo Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months. https://clinicaltrials.gov/ct2/show/NCT01194154
817399 NCT01179048 Drug liraglutide Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject’s standard treatment https://clinicaltrials.gov/ct2/show/NCT01179048
817400 NCT01179048 Drug placebo Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject’s standard treatment https://clinicaltrials.gov/ct2/show/NCT01179048
821474 NCT01147250 Drug Lixisenatide (AVE0010) Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg. https://clinicaltrials.gov/ct2/show/NCT01147250
821475 NCT01147250 Drug Placebo Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast. https://clinicaltrials.gov/ct2/show/NCT01147250
821976 NCT01143272 Drug Saccharomyces boulardii Units: 500 mg per day Route of administration : Oral Use Hard-Capsule https://clinicaltrials.gov/ct2/show/NCT01143272
821977 NCT01143272 Drug Placebo Placebo https://clinicaltrials.gov/ct2/show/NCT01143272
822063 NCT01142596 Drug Asenapine Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID https://clinicaltrials.gov/ct2/show/NCT01142596
822064 NCT01142596 Drug Placebo Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only) https://clinicaltrials.gov/ct2/show/NCT01142596
825558 NCT01115855 Drug Eplerenone Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily https://clinicaltrials.gov/ct2/show/NCT01115855
825559 NCT01115855 Drug Placebo Placebo once daily or every once daily https://clinicaltrials.gov/ct2/show/NCT01115855
826787 NCT01106014 Drug Selexipag Selexipag 200 mcg tablets https://clinicaltrials.gov/ct2/show/NCT01106014
826788 NCT01106014 Drug Placebo Selexipag matching placebo tablets https://clinicaltrials.gov/ct2/show/NCT01106014
832920 NCT01057810 Drug Ipilimumab 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure https://clinicaltrials.gov/ct2/show/NCT01057810
832921 NCT01057810 Drug Placebo Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure https://clinicaltrials.gov/ct2/show/NCT01057810
840164 NCT01002742 Drug Mycophenolate Mofetil Oral dosing should be delivered in 250 mg units. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 6 0 kg should receive MMF 1 gm PO/IV every 8 hours.
Patients who weight bet ween 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 2 0 mg/kg IV or PO every 8 hours. https://clinicaltrials.gov/ct2/show/NCT01002742
840165 NCT01002742 Drug Placebo Oral dosing should be delivered in 250 mg units blinded placebo. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 6 0 kg should receive placebo 1 gm PO/IV every 8 hours.
Patients who weight bet ween 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 2 0 mg/kg IV or PO every 8 hours. https://clinicaltrials.gov/ct2/show/NCT01002742
846721 NCT00955825 Drug 300 IR 300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season https://clinicaltrials.gov/ct2/show/NCT00955825
846722 NCT00955825 Drug Placebo Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season https://clinicaltrials.gov/ct2/show/NCT00955825
850083 NCT00931528 Drug Tadalafil Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks. https://clinicaltrials.gov/ct2/show/NCT00931528
850084 NCT00931528 Other Placebo Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks. https://clinicaltrials.gov/ct2/show/NCT00931528
859763 NCT00861614 Drug Ipilimumab 5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure https://clinicaltrials.gov/ct2/show/NCT00861614
859764 NCT00861614 Drug Placebo Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure https://clinicaltrials.gov/ct2/show/NCT00861614
861553 NCT00847912 Drug 5-fluorouracil Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate “cool-down” treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the “cool-down” routine will be followed, but 5-FU will be stopped. https://clinicaltrials.gov/ct2/show/NCT00847912
861554 NCT00847912 Drug Placebo, vehicle control Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate “cool-down” treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the “cool-down” routine will be followed, but vehicle control cream will be stopped. https://clinicaltrials.gov/ct2/show/NCT00847912
867439 NCT00804570 Drug LY2196044 250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks https://clinicaltrials.gov/ct2/show/NCT00804570
867440 NCT00804570 Drug placebo once daily, orally, 16 weeks https://clinicaltrials.gov/ct2/show/NCT00804570
867614 NCT00803244 Drug 300 IR 300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season https://clinicaltrials.gov/ct2/show/NCT00803244
867615 NCT00803244 Drug Placebo Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season https://clinicaltrials.gov/ct2/show/NCT00803244
869209 NCT00791648 Drug atorvastatin Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 inte rvention: ator vastatin 80mg the da y of cardiac surgery and 40mg on postop day 1. https://clinicaltrials.gov/ct2/show/NCT00791648
869210 NCT00791648 Drug placebo Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 con trol: placebo the day of cardiac s urgery and postop day 1. https://clinicaltrials.gov/ct2/show/NCT00791648
869410 NCT00790205 Drug Sitagliptin Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily. https://clinicaltrials.gov/ct2/show/NCT00790205
869411 NCT00790205 Drug Placebo Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily. https://clinicaltrials.gov/ct2/show/NCT00790205
869910 NCT00786474 Drug Placebo Normal saline solution, dosage determined by weight, self-administered by patient twice a day https://clinicaltrials.gov/ct2/show/NCT00786474
869911 NCT00786474 Drug Dalteparin Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day https://clinicaltrials.gov/ct2/show/NCT00786474
884838 NCT00674973 Drug Erlotinib Participants received erlotinib 150 mg tablet orally once daily. https://clinicaltrials.gov/ct2/show/NCT00674973
884839 NCT00674973 Drug Placebo Participants received placebo matching to erlotinib 150 mg tablet orally once daily. https://clinicaltrials.gov/ct2/show/NCT00674973
886253 NCT00665626 Drug Fostamatinib disodium (R935788) R935788 100 mg tablet, orally, twice-a-day https://clinicaltrials.gov/ct2/show/NCT00665626
886254 NCT00665626 Drug Placebo Placebo, orally, twice-a-day https://clinicaltrials.gov/ct2/show/NCT00665626
889568 NCT00642993 Drug SCH 497079 100 mg capsule administered orally https://clinicaltrials.gov/ct2/show/NCT00642993
889569 NCT00642993 Drug Placebo Placebo capsules matching SCH 497079 administered orally https://clinicaltrials.gov/ct2/show/NCT00642993
890366 NCT00637494 Drug mifepristone 1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days https://clinicaltrials.gov/ct2/show/NCT00637494
890367 NCT00637494 Drug placebo Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days https://clinicaltrials.gov/ct2/show/NCT00637494
900384 NCT00561678 Drug Precedex (Dexmedetomidine) 0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively. https://clinicaltrials.gov/ct2/show/NCT00561678
900385 NCT00561678 Drug Placebo 0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively. https://clinicaltrials.gov/ct2/show/NCT00561678
904061 NCT00536198 Drug Sertraline 50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue. https://clinicaltrials.gov/ct2/show/NCT00536198
904062 NCT00536198 Drug Placebo 50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. https://clinicaltrials.gov/ct2/show/NCT00536198
906164 NCT00520286 Drug Modafinil 200 mg or 400 mg /daily https://clinicaltrials.gov/ct2/show/NCT00520286
906165 NCT00520286 Drug Placebo Placebo / daily https://clinicaltrials.gov/ct2/show/NCT00520286
908240 NCT00504881 Drug Placebo Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period https://clinicaltrials.gov/ct2/show/NCT00504881
908241 NCT00504881 Drug Brivaracetam Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period https://clinicaltrials.gov/ct2/show/NCT00504881
910380 NCT00488618 Drug Cariprazine (RGH-188) Cariprazine 3 mg - 12 mg oral administration, once per day. https://clinicaltrials.gov/ct2/show/NCT00488618
910381 NCT00488618 Drug Placebo Dose-matched placebo oral administration, once per day. https://clinicaltrials.gov/ct2/show/NCT00488618
920736 NCT00409409 Drug 300 IR grass pollen allergen extract tablet One sublingual tablet daily during 4 months before pollen season and during pollen season https://clinicaltrials.gov/ct2/show/NCT00409409
920737 NCT00409409 Drug Placebo tablet One sublingual tablet daily during 4 months before pollen season and during pollen season https://clinicaltrials.gov/ct2/show/NCT00409409
931823 NCT00319501 Drug Placebo Intramuscular autoinjector; administered at onset of an episode https://clinicaltrials.gov/ct2/show/NCT00319501
931824 NCT00319501 Drug Vanquix Auto-Injector (Diazepam Injection) Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant’s age and weight); administered at the onset of an episode https://clinicaltrials.gov/ct2/show/NCT00319501
941523 NCT00240981 Drug Topical testosterone gel 1% (active formulation) Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day. https://clinicaltrials.gov/ct2/show/NCT00240981
941524 NCT00240981 Drug Topical gel (placebo formulation) Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day. https://clinicaltrials.gov/ct2/show/NCT00240981
943760 NCT00220961 Drug Pioglitazone Pioglitazone tablets - 45 mg/day https://clinicaltrials.gov/ct2/show/NCT00220961
943761 NCT00220961 Drug Placebo Placebo tablets similar to pioglitazone tablets - 1 tablet/day https://clinicaltrials.gov/ct2/show/NCT00220961
959008 NCT00091949 Drug pioglitazone a thiazolidinedione drug https://clinicaltrials.gov/ct2/show/NCT00091949
959009 NCT00091949 Drug placebo an inactive substance https://clinicaltrials.gov/ct2/show/NCT00091949
970406 NCT00008385 Other placebo Given orally https://clinicaltrials.gov/ct2/show/NCT00008385
970407 NCT00008385 Drug selenium Given orally https://clinicaltrials.gov/ct2/show/NCT00008385
989300 NCT01753076 Drug Ozanezumab Ozanezumab injection solution https://clinicaltrials.gov/ct2/show/NCT01753076
989301 NCT01753076 Drug Placebo Normal saline (0.9% sodium chloride) infusion https://clinicaltrials.gov/ct2/show/NCT01753076